REVISE-Diabesity trial to compare Endobarrier + Liraglutide vs. Liraglutide alone for refractory T2DM/obesity.
Randomisation to Endobarrier Alone Versus With Incretin Analogue in SustainEd Diabesity (REVISE-Diabesity)
Abstract
A randomized trial will compare Endobarrier + Liraglutide 1.2mg vs. Liraglutide 1.8mg alone in 72 patients with refractory Type 2 Diabetes and obesity.